Michael Morrissey

“Before I begin, let me just remind, do my safe harbor. I'll be making four looking statements today, so please see our SEC filings for a description of the risks that we face in our business.”

“That's Alexis continues to execute across the key elements of our business, positioning the company to deliver on our strategic objectives for 2026 and beyond.”

“Yeah, I mean, you know, I would certainly say kind of taking a step back, everything we do at Exlexis is kind of through what we call the Cabo lens, you know, learning what's been successful, learning, you know, what to do right, learning kind of areas that we should avoid in the future.”

“And thanks to everyone for joining us on the call today. 2025 was a transformational year for Exelixis, with strong growth across all components of our business.”

“Exelixis had a strong third quarter, building on our progress from the first half of 2025. Accelerating R&D momentum coupled with flawless commercial execution has the potential to transform our business as we bring new treatment options to patients and build value for shareholders.”